# Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Source: https://onco.cc/trials/nct06141070/  
OnCo record `nct06141070` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Vastra Gotaland Region, now recruiting.

## Summary

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease is a phase 3, randomised interventional study registered as NCT06141070 by Vastra Gotaland Region, with a registry enrolment figure of 240 participants, started 2023-12-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Standard systemic therapy + radiotherapy; Standard systemic therapy. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "* Histological or cytological diagnosis of NSCLC". Sites: Sweden. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: ANDROMEDA
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06141070
- Phase: 3
- Setting: Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - An Open Label Randomized Phase III Trial Comparing Up-front Radiation in Oligometastatic Non-small Cell Lung Cancer (NSCLC) and Systemic Treatment With Systemic Treatment Alone
- Sponsor: Vastra Gotaland Region
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT06141070: https://clinicaltrials.gov/study/NCT06141070

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06141070.json